Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure
Guillermo Torre‐Amione(Baylor College of Medicine), Isaac Kobrin(Actelion (Switzerland)), Maurizio Rainisio(Actelion (Switzerland)), John R. Teerlink(University of Glasgow), Wilson S. Colucci(Boston University), Uri Elkayam(Icahn School of Medicine at Mount Sinai), Aline Frey(Actelion (Switzerland)), Gad Cotter(Momentum Research), Craig M. Pratt(Baylor College of Medicine), James B. Young(Houston Methodist), Karl Stangl(German Centre for Cardiovascular Research), Basil S. Lewis(Technion – Israel Institute of Technology)
Cited by 119
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Contemporary Definitions and Classification of the Cardiomyopathies
|Circulation|2006|3.4k
Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
|The Lancet|1996|1.4k
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
|Circulation|2004|1.2k